Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2023 / N 1

Амантадин в современной неврологической практике
А.А. Пилипович, В.Л. Голубев

Список литературы

1. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA 1969 May;208(7):1168-70.
2. Silver DE, Sahs AL. Double blind study using amantadine hydrochloride in the therapy of Parkinson’s disease. Transactions of the American Neurological Association 1971;96:307-8.
3. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 1998 May;50(5):1323-6.
4. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Archives of Neurology 1999 Nov;56(11):1383-6.
5. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Movement Disorders 2010 Jul;25(10):1357-63.
6. Butterworth RF. Amantadine for the treatment of traumatic brain injury and its associated cognitive and neurobehavioral complications. Journal of Pharmacology and Pharmaceutical Research 2020;3(1):1-5. Available from: https://researchopenworld.com/amantadine-for-the-treatment-of-traumatic-brain-injury-and-its-associated-cognitive-and-neurobehavioral-complications/ Accessed 2023 Mar 31.
7. Рамазанов Г.Р., Ковалева Э.А., Шевченко Е.В., Ахматханова Л.Х. Применение амантадина сульфата при ишемическом инсульте. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски 2020;120(122):569.
8. Butterworth RF. Amantadine, Parkinson’s disease and COVID-19. COVID-19 Pandemic: Case Studies & Options 2020 Jun;01(02):21-6. Available from: https://researchinfotext.com/article-details/Amantadine-Parkinson-rsquo-s-Disease-and-COVID-19/ Accessed 2023 Mar 31.
9. Quarato G, Scrima R, Ripoli M, Agriesti F, Moradpour D, Capitanio N, Piccoli C. Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression. Biochemical Pharmacology 2014 Jun;89(4):545-56.
10. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders 2020 Jul;42:102163.
11. Danysz W, Dekundy A, Scheschonka A, Riederer P. Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials. Journal of Neural Transmission (Vienna, Austria: 1996) 2021 Feb;128(2):127-69.
12. Chang C, Ramphul K. Amantadine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499953/ Accessed 2023 Mar 31.
13. Gerzon K, Krumkalns EV, Brindle RL, Marshall FJ, Root MA. The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N’-adamantylureas. Journal of Medicinal Chemistry 1963 Nov;6:760-3.
14. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012 Apr;78(14):1096-9.
15. Maugh TH 2nd. Panel urges wide use of antiviral drug. Science 1979 Nov;206(4422):1058-60.
16. Zimmermann M. Periodic safety update report for PK-Merz active: amantadine sulphate. Report. Frankfurt: Merz Pharmaceuticals; 1997.
17. Crane GE. More on amantadine in tardive dyskinesia. The New England Journal of Medicine 1971 Nov;285(20):1150-1.
18. Scotti G, Spinnler H. Amantadine and Huntington’s chorea. The New England Journal of Medicine 1971 Dec;285(23):1325-6.
19. Danielczyk W. [Therapy of akinetic crises.] Die Medizinische Welt 1973 Aug;24(33):1278-82.
20. Manyam BV. Amantadine in essential tremor. Annals of Neurology 1981 Feb;9(2):198-9.
21. Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. European Journal of Pharmacology 1989 Aug;166(3):589-90.
22. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: a new clinical profile for traumatic brain injury. Clinical Neuropharmacology 1989 Aug;12(4):258-70. 23. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. European Journal of Pharmacology 1991 Apr;206(4):297-300.
24. Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neuroscience Letters 1993 Dec;163(2):129-31.
25. Rajput A, Wallkait M, Rajput AH. 18-month prospective study of amantadine (AMD) for Dopa(LD) induced dyskinesias (DK) in idio­pathic Parkinson’s disease. Canadian Journal of Neurological Sciences 1997;24:S23.
26. Highlights of prescribing information. GOCOVR™ (amantadine) Adamas Pharma, LLC. 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208944lbl.pdf Accessed 2023 Mar 31.
27. Никонов В.В., Савицкая И.Б. Роль антагонистов глутаматных рецепторов (ПК-Мерц) в лечении повреждений мозга (обзор литературы). Медицина неотложных состояний 2012;5(44):36-9.
28. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson’s disease. Journal of Neural Transmission. Supplementum 1995;46:399-405. 29. Левин О.С., Федорова Н.В. Болезнь Паркинсона. 4-е изд. М.: МЕДпресс-информ; 2014. 384 с.
30. Инструкция по применению ПК-Мерц. Доступно по: https://merz.ru/catalog/nevrologiya/pk-merts/ Ссылка активна на 31.03.2023.
31. Инструкция по применению амантадина. Доступно по: https://www.rlsnet.ru/active-substance/amantadin-845/ Ссылка активна на 31.03.2023.
32. Turski L, Bressler K, Rettig KJ, Löschmann A, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991 Jan;349(6308):414-8.
33. Sommerauer C, Rebernik P, Reither H, Nanoff C, Pifl C. The nor­adrenaline transporter as site of action for the anti-Parkinson drug amantadine. Neuropharmacology 2012 Mar;62(4):1708-16.
34. Rojas P, Altagracia M, Kravzov J, Rios C. Amantadine increases striatal dopamine turnover in MPTP-treated mice. Drug Development Research 1993 Jul;29(3):222-6.
35. Ossola B, Schendzielorz N, Chen SH, Bird GS, Tuominen RK, Männistö PT, Hong JS. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 2011 Sep;61(4):574-82.
36. Kranthi K, Priya VVMA, Punnagai K, David DC. A comparative free radical scavenging evaluation of amantadine and rasagiline. Biomedical and Pharmacology Journal 2019 Aug;12(3):1175-9.
37. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. European Journal of Pharmacology 1995 Oct;293(3):267-70.
38. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 1996 Jun;46(6):1551-6.
39. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson’s disease. Molecular Neurobiology 1996 Feb;12(1):73-94.
40. National Collaborating Centre for Chronic Conditions (UK). Parkinson’s disease: National clinical guideline for diagnosis and management in primary and secondary care. National Institute for Health and Clinical Excellence (NICE) Clinical Guideline (CG 35). London: Royal College of Physicians (UK); 2006: 1-45.
41. Dallos V, Heathfield K, Stone P, Allen FA. Use of amantadine in Parkinson’s disease. Results of a double-blind trial. British Medical Journal 1970 Oct;4(5726):24-6.
42. Greulich W, Fenger E. Amantadine in Parkinson’s disease: pro and contra. Journal of Neural Transmission. Supplementum 1995;46:415-21.
43. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson’s disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 1975 Jul;25(7):603-6.
44. Factor SA, Molho ES. Transient benefit of amantadine in Parkinson’s disease: the facts about the myth. Movement Disorders 1999 May;14(3):515-7.
45. Chung JS, Wu AD, Lew MF. Amantadine and anticholinergics. New York: Marcel Dekker; 2003. 18 p.
46. Inzelberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R, Logi C, Rossi C, Klein C, Rabey JM. Association between amantadine and the onset of dementia in Parkinson’s disease. Movement Disorders 2006 Sep;21(9):1375-9.
47. Fahn S, Isgreen WP. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1975 Aug;25(8):695-700.
48. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994 Dec;5(18):2586-8.
49. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Annals of Neurology 1996 May;39(5):574-8.
50. Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez-Jimenez N. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Movement Disorders 1998 Sep;13(5):851.
51. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders 2001 May;16(3):515-20.
52. da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism & Related Disorders 2005 Nov;11(7):449-52.
53. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T; Amantadine Study Group. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One 2010 Dec;5(12):e15298.
54. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clinical Neuropharmacology 2000 Mar-Apr;23(2):82-5.
55. Luginger E, Wenning GK, Bösch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Movement Disorders 2000 Sep;15(5):873-8.
56. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 2004 Jan;75(1):141-3.
57. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014 Jan;82(4):300-7.
58. Haoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clinical Pharmacokinetics 1988 Jan;14(1):35-51.
59. Elahi B, Phielipp N, Chen R. N-methyl-D-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Canadian Journal of Neurological Sciences 2012 Jul;39(4):465-72.
60. Brenner M, Haass A, Jacobi P, Schimrigk K. [Intravenous and oral treatment with amantadine sulfate in Parkinson disease.] Der Nervenarzt 1988 Mar;59(3):180-4.
61. Müller T, Kuhn W, Schulte T, Przuntek H. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease. Neuroscience Letters 2003 Mar;339(1):25-8.
62. Бойко А.Н., Барышева Т.Т., Викина Е.С. Эффективность использования ПК-Мерца при болезни Паркинсона в амбулаторной практике. Лечение нервных болезней 2004;2(14):20.
63. Федорова Н.В., Ветохина Т.Н. Диагностика и лечение нейролептических экстрапирамидных синдромов. Учебно-методическое пособие. М.: РАМПО; 2006. 36 с.
64. Карабань И.Н. Применение блокатора глутаматных рецепторов амантадина в неврологии. Международный неврологический журнал 2012;2(48):195-201.
65. Левин О.С., Иллариошкин С.Н., Голубев В.Л. Экстрапирамидные расстройства. Руководство для врачей. М.: Медпресс-информ; 2022. 772 с.
66. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology 1997 Apr;17(2):88-91.
67. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology 2010 Nov-Dec;33(6):271-5.
68. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. Journal of Neurology Sciences 2018 Jun;389:67-75.
69. Thibaut A, Schiff N, Giacino J, Laureys S, Gosseries O. Therapeutic interventions in patients with prolonged disorders of consciousness. The Lancet. Neurology 2019 Jun;18(6):600-14.
70. Peoples J, Lopez AJ, Feeko KJ, Ng L, Gobrial M, Shah O, Vibbert M, Urtecho J, Jallo J, Bell R, Rincon F, Bar B, Athar M. Stimulant use to improve wakefulness following brain injury: a survey of the Neurocritical Care Society. EC Neurology 2020;12:01-06.
71. Rühl L, Kuramatsu JB, Sembill JA, Kallmünzer B, Madzar D, Gerner ST, Giede-Jeppe A, Balk S, Mueller T, Jäger J, Schwab S, Huttner HB, Sprügel MI. Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury. Journal of Neurology, Neurosurgery and Psychiatry 2022 Jun;93(6):582-7.
72. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. The Journal of Head Trauma Rehabilitation 2002 Aug;17(4):300-13.
73. Steube D, Goertelmeyer R. The influence of amantadine sulfate on disturbances of arousal after severe traumatic brain injury. Neurologie und Rehabilitation 2000 Jan;6(6):307-12.
74. Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, Yablon SA, Luther M, Hammond FM, Nordenbo A, Novak P, Mercer W, Maurer-Karattup P, Sherer M. Placebo-controlled trial of amantadine for severe traumatic brain injury. The New England Journal of Medicine 2012;366(9):819-26.
75. Gagnon DJ, Leclerc AM, Riker RR, Brown CS, May T, Nocella K, Cote J, Eldridge A, Seder DB. Amantadine and modafinil as neurostimulants during post-stroke care: a systematic review. Neurocritical Care 2020 Aug;33(1):283-97.
76. Leclerc AM, Riker RR, Brown CS, May T, Nocella K, Cote J, Eldridge A, Seder DB, Gagnon DJ. Amantadine and modafinil as neurostimulants following acute stroke: a retrospective study of Intensive Care Unit patients. Neurocritical Care 2021 Feb;34(1):102-11.
77. Белкин А.А., Щеголев А.В., Кондратьев А.Н., Бубнова И.Д., Тукмарова Р.Р., Алашеев А.М., Бельский Д.В., Вол А.Е., Доманский Д.С., Почепко Д.В., Истомин В.В., Сурков М.В., Боровикова В.Н., Кондратьева Е.А., Лестева Н.А., Малешина Н.И., Назаров Р.А., Ценципер В.М., Шестов А.В. ПК-Мерц при вегетативном статусе и “малом сознании”. Интенсивная терапия 2007;1:15-9. Доступно по: https://icj.ru/journal/number-1-2007/97-pk-merc-pri-vegetativnom-statuse-i-malom-soznanii.html/ Ссылка активна на 31.03.2023.
78. Lehnerer SM, Scheibe F, Buchert R, Kliesch S, Meisel A. Awakening with amantadine from a persistent vegetative state after subarachnoid haemorrhage. BMJ Case Reports 2017 Jul;2017:bcr2017220305.
79. Gao Y, Zhang Y, Li Z, Ma L, Yang J. Persistent vegetative state after severe cerebral hemorrhage treated with amantadine: a retrospective controlled study. Medicine 2020 Aug;99(33):e21822.
80. Akçıl EF, Dilmen ÖK, Vehid H, Tunalı Y. Can amantadine ameliorate neurocognitive functions after subarachnoid haemorrhage? A preliminary study. Turkish Journal of Anaesthesiology & Reanimation 2018 Apr;46(2):100-7.
81. Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation. Brain Injury 1994 Nov-Dec;8(8):709-18. 82. Chen YW, Shieh JP, Chen YC, Leung YM, Hung CH, Wang JJ. Cutaneous analgesia after subcutaneous injection of memantine and amantadine and their systemic toxicity in rats. European Journal of Pharmacology 2012 Oct;693(1-2):25-30.
83. Aiyer R, Mehta N, Gungor S, Gulati A. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. The Clinical Journal of Pain 2018 May;34(5):450-67.
84. Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabetic Medicine 2003 Feb;20(2):114-8.
85. Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo-controlled trial. Pain 1998 Apr;75(2-3):349-54.
86. Chiba S, Ito M, Matsumoto H. Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis. Canadian Journal of Neurological Sciences 1992 May;19(2):309.
87. Galbraith AW. Treatment of acute herpes zoster with amantadine hydrochloride (Symmetrel). British Medical Journal 1973 Dec;4(5894):693-5.
88. Medrik-Goldberg T, Lifschitz D, Pud D, Adler R, Eisenberg E. Intravenous lidocaine, amantadine, and placebo in the treatment of sciatica: a double-blind, randomized, controlled study. Regional Anesthesia & Pain Medicine 1999 Nov-Dec;24(6):534-40.
89. Gottschalk A, Schroeder F, Ufer M, Oncü A, Buerkle H, Standl T. Amantadine, a N-methyl-D-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy. Anesthesia & Analgesia 2001 Jul;93(1):192-6.
90. Eisenberg E, Pud D, Koltun L, Loven D. Effect of early administration of the N-methyl-D-aspartate receptor antagonist amantadine on the development of postmastectomy pain syndrome: a prospective pilot study. Journal of Pain 2007 Mar;8(3):223-9.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]